Deutsche Bank AG Invests $3.60 Million in Halozyme Therapeutics, Inc. $HALO

Key Points

• Deutsche Bank acquired a new $3.6 million stake in Halozyme Therapeutics during the second quarter, while institutional investors collectively own 97.79% of the company.
• Halozyme reported stronger-than-expected quarterly results, with EPS of $2.28 versus the $1.79 consensus estimate and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating from 13 analysts and a $91.20 average price target, although insiders sold 64,103 shares worth about $5.23 million in the last quarter.

Deutsche Bank AG bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 45,987 shares of the biopharmaceutical company's stock, valued at approximately $3,599,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Halozyme Therapeutics in the second quarter valued at about $28,000. OneDigital Investment Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $254,000. Chase Investment Counsel Corp acquired a new position in shares of Halozyme Therapeutics during the second quarter worth $2,035,000. Horizon Investment Services LLC acquired a new position in shares of Halozyme Therapeutics during the second quarter worth $2,254,000. Finally, Global Retirement Partners LLC purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at $476,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $107.06 on Thursday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $109.66. The firm's 50-day simple moving average is $85.50 and its 200-day simple moving average is $74.39. The firm has a market cap of $12.15 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 0.44 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period last year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Bernadette Connaughton sold 1,626 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company's stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,103 shares of company stock valued at $5,226,496 in the last quarter. Insiders own 2.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on HALO shares. Morgan Stanley lowered their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a report on Tuesday, May 12th. Citigroup restated a "market outperform" rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Wall Street Zen upgraded Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. Finally, Leerink Partners raised Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and upped their target price for the company from $83.00 to $110.00 in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source